In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model

Suresh R. Pai; Kavindra V. Singh; Barbara E. Murray

doi:10.1128/AAC.47.8.2706-2709.2003

In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model

Suresh R. Pai, Kavindra V. Singh, Barbara E. Murray

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Ery^s) and -intermediate (Eryⁱ) enterococci (ABT 50% protective doses [PD₅₀s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Ery^r) strains for which ABT MICs were low, ABT showed much greater activity (PD₅₀, 6.3 to 32.5 mg/kg) than ERY (PD₅₀, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.

Original language	English (US)
Pages (from-to)	2706-2709
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	47
Issue number	8
DOIs	https://doi.org/10.1128/AAC.47.8.2706-2709.2003
State	Published - Aug 1 2003

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.47.8.2706-2709.2003

Cite this

@article{7ba29e213cf542e69eb76df6dde98961,

title = "In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model",

abstract = "Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50\% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.",

author = "Pai, \{Suresh R.\} and Singh, \{Kavindra V.\} and Murray, \{Barbara E.\}",

year = "2003",

month = aug,

day = "1",

doi = "10.1128/AAC.47.8.2706-2709.2003",

language = "English (US)",

volume = "47",

pages = "2706--2709",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model

AU - Pai, Suresh R.

AU - Singh, Kavindra V.

AU - Murray, Barbara E.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.

AB - Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.

UR - https://www.scopus.com/pages/publications/0041767388

UR - https://www.scopus.com/inward/citedby.url?scp=0041767388&partnerID=8YFLogxK

U2 - 10.1128/AAC.47.8.2706-2709.2003

DO - 10.1128/AAC.47.8.2706-2709.2003

M3 - Article

C2 - 12878548

AN - SCOPUS:0041767388

SN - 0066-4804

VL - 47

SP - 2706

EP - 2709

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 8

ER -

In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this